Obstructive Hypertrophic Cardiomyopathy Clinical Trial
Official title:
To Evaluate the Safety and Feasibility of the DragonFire Transcatheter Radiofrequency Myocardial Ablation System
This is a prospective, single-center, single-arm clinical study. All patients were diagnosed with obstructive hypertrophic cardiomyopathy, and only subjects who met the instrument indications of this study were treated. After signing an informed consent form, subjects are enrolled and treated with the DragonFire Transcatheter Myocardial Ablation System. All subjects receive clinical follow-up immediately after the procedure, before discharge, 30 days after the procedure, 6 months after the procedure, and 12 months after the procedure.
This is a prospective, single-center, single-arm clinical study. All patients were diagnosed with obstructive hypertrophic cardiomyopathy, and only subjects who met the instrument indications of this study were treated. After signing an informed consent form, subjects are enrolled and treated with the DragonFire Transcatheter Myocardial Ablation System. The primary efficacy endpoint was the rate of major adverse events 30 days after surgery. The safety endpoints were the rate of immediate postoperative success and postoperative device success All subjects receive clinical follow-up immediately after the procedure, before discharge, 30 days after the procedure, 6 months after the procedure, and 12 months after the procedure. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06023186 -
Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
|
||
| Completed |
NCT05726799 -
Use of Cryoenergy to Faciltate Myectomy in Hypertrophic Obstructive Cardiomyopathy: Comparison With the Classical Approach
|
||
| Active, not recruiting |
NCT03723655 -
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
|
Phase 2/Phase 3 | |
| Completed |
NCT04603521 -
Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
|
||
| Recruiting |
NCT06116968 -
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
|
Phase 3 | |
| Completed |
NCT03470545 -
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
|
Phase 3 | |
| Recruiting |
NCT05879523 -
A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy
|
Phase 1 | |
| Not yet recruiting |
NCT06146660 -
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
|
||
| Recruiting |
NCT05771987 -
Permanent Pacing for Drug-refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
|
N/A | |
| Active, not recruiting |
NCT05174416 -
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
|
Phase 3 | |
| Recruiting |
NCT06224621 -
Percutaneous Endocardial Septal Radiofrequency Ablation in Obstructive Hypertrophic Cardiomyopathy
|
N/A | |
| Completed |
NCT01631006 -
Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy
|
N/A | |
| Not yet recruiting |
NCT06368037 -
Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy
|
N/A | |
| Recruiting |
NCT05489705 -
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM)
|
||
| Completed |
NCT06354556 -
Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04783766 -
Safety, Tolerability and Pharmacokinetics Study of CK-3773274
|
Phase 1 |